3 min readJun 5, 2026 07:19 AM IST
First published on: Jun 4, 2026 at 09:35 PM IST
Two commonly used, affordable chemotherapy medicines — Cisplatin and Carboplatin — have gone off the shelves across the country over the last two weeks, prompting oncologists to raise an alarm. This is because of the increase in prices of raw materials, fuelled by the Hormuz crisis, and the inability of companies to raise prices since they are under the government’s price control ambit, according to industry experts.
“Our hospital pharmacy has run out of Cisplatin and Carboplatin. Nearly seven in 10 patients in my clinic need one of these drugs. They are prescribed for oral, lung, cervical, oesophageal, ovarian, and breast cancer, among others. Now, we have cancer patients running from one store to the other in search of this medicine. My colleagues in other cities are also facing a similar situation,” said Dr Shyam Agarwal, chairman of medical oncology at Sir Gangaram Hospital.
Dr Abhishek Shankar, oncologist from the All India Institute of Medical Sciences (AIIMS), New Delhi, echoed a similar concern: “There has been a shortage of these drugs for at least the last two weeks.” Another Delhi-based oncologist said that lower doses have completely gone off the shelves though higher doses are still available in some stores.
In Mumbai, Dr Mohan Menon, medical oncologist at Lilavati Hospital and Research Centre, said that there has been a shortage of all platinum-derived chemotherapy agents, adding the root cause of the failure is the increase in prices of platinum globally. “This precious metal was trading at Rs 2,700 per gram in mid-2023 but has now skyrocketed to over Rs 7,800 per gram,” he said.
Wholesalers and stockists, meanwhile, are fast running out of supplies. The owner of a major retail pharmacy in Delhi said: “Almost no medical store in the country has these medicines at the moment. Most stockists and wholesalers have run out of them. With the limited stock they have, they are saying they will sell it directly to patients instead of retailers.”
While the increasing cost of raw materials has elevated prices of many medical products, especially those based on petrochemicals, since the start of the war, the companies producing these two drugs have maintained the prices. These medicines come under Drug Pricing Control Order (DPCO), which regulates the prices of all essential medicines in the country. Any drug under the DPCO can only increase its price in tandem with the average rise in wholesale prices each year.
While the prices of platinum have been going up — owing to a deficit in the world’s largest supplier, South Africa, and the growing usage of the metal in the automotive sector besides in production of green hydrogen — the current West Asia crisis has added fuel to the fire. “Most of India’s platinum is imported from Gulf countries, which have been impacted due to the current conflict,” said an industry expert, who did not wish to be named. United Arab Emirates is the biggest supplier of platinum for India, accounting for nearly half the imports.
While the increasing cost of raw materials has elevated prices of many medical products since the start of the war — especially those based on petrochemicals — the companies producing these two drugs have not. (Photo: Pixabay) 
Share
